About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Tacc3tm1.2Tno
targeted mutation 1.2, Tetsuo Noda
MGI:3763219
Summary 5 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
 		Tacc3tm1.2Tno/Tacc3tm1.2Tno involves: C57BL/6 MGI:3763274
ht2
 		Tacc3tm1.1Tno/Tacc3tm1.2Tno involves: C57BL/6 MGI:3763271
ht3
 		Tacc3tm1Tno/Tacc3tm1.2Tno involves: C57BL/6 MGI:3763275
cn4
 		Tacc3tm1.1Tno/Tacc3tm1.2Tno involves: C57BL/6 MGI:3763272
cn5
 		Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
Tacc3tm1.1Tno/Tacc3tm1.2Tno
Trp53tm1Tyj/Trp53tm1Tyj 		involves: 129S2/SvPas * 129S4/SvJae * C57BL/6 MGI:5305073


Genotype
MGI:3763274
hm1
Allelic
Composition		 Tacc3tm1.2Tno/Tacc3tm1.2Tno
Genetic
Background		 involves: C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tacc3tm1.2Tno mutation (0 available); any Tacc3 mutation (29 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging

growth/size/body
embryonic growth retardation ( J:126471 )
• severe growth retardation is evident at E9.0

embryo
embryonic growth retardation ( J:126471 )
• severe growth retardation is evident at E9.0




Genotype
MGI:3763271
ht2
Allelic
Composition		 Tacc3tm1.1Tno/Tacc3tm1.2Tno
Genetic
Background		 involves: C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tacc3tm1.1Tno mutation (0 available); any Tacc3 mutation (29 available)
Tacc3tm1.2Tno mutation (0 available); any Tacc3 mutation (29 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
normal phenotype
no abnormal phenotype detected ( J:126471 )
• mice are born at Mendelian ratios and no overt abnormalities are detected




Genotype
MGI:3763275
ht3
Allelic
Composition		 Tacc3tm1Tno/Tacc3tm1.2Tno
Genetic
Background		 involves: C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tacc3tm1.2Tno mutation (0 available); any Tacc3 mutation (29 available)
Tacc3tm1Tno mutation (0 available); any Tacc3 mutation (29 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging

growth/size/body
embryonic growth retardation ( J:126471 )
• growth retardation is evident at E9.5 but is milder than in Tacc3tm1.2Tno homozygotes

embryo
embryonic growth retardation ( J:126471 )
• growth retardation is evident at E9.5 but is milder than in Tacc3tm1.2Tno homozygotes




Genotype
MGI:3763272
cn4
Allelic
Composition		 Tacc3tm1.1Tno/Tacc3tm1.2Tno
Genetic
Background		 involves: C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tacc3tm1.1Tno mutation (0 available); any Tacc3 mutation (29 available)
Tacc3tm1.2Tno mutation (0 available); any Tacc3 mutation (29 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
cellular
abnormal mitosis ( J:126471 )
• 36% of mouse embryonic fibroblasts (MEFs) transfected with an adenovirus cre vector exhibit abnormal mitosis similar to in Tacc3tm1Tno MEFs and produce binucleated cells, 7.8% of cells produce 3 or 4 cells after cytokinesis and 22% of cells fail to separate sister chromatids
• however, 37% of transfected MEFs complete mitosis normally




Genotype
MGI:5305073
cn5
Allelic
Composition		 Gt(ROSA)26Sortm1(cre/ERT2)Tyj/Gt(ROSA)26Sor+
Tacc3tm1.1Tno/Tacc3tm1.2Tno
Trp53tm1Tyj/Trp53tm1Tyj
Genetic
Background		 involves: 129S2/SvPas * 129S4/SvJae * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm1(cre/ERT2)Tyj mutation (3 available); any Gt(ROSA)26Sor mutation (993 available)
Tacc3tm1.1Tno mutation (0 available); any Tacc3 mutation (29 available)
Tacc3tm1.2Tno mutation (0 available); any Tacc3 mutation (29 available)
Trp53tm1Tyj mutation (12 available); any Trp53 mutation (240 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
increased T cell derived lymphoma incidence ( J:179414 )
• in the absence of 4OHT, mutants develop thymic lymphoma tumors
decreased lymphoma incidence ( J:179414 )
• administration of 4-hydroxytamoxifen (4OHT) to induce Cre recombination results in regression of autochthonous thymic lymphoma, with a reduction in tumor volume to 96% and 26% of original volume, over 3 and 10 days, respectively
• regression of tumors is due to apoptosis in thymic lymphoma
• 4OHT treatment of mutants results in massive apoptosis in thymic lymphomas but not in normal thymic tissue or other tissues
• lymphoma cells contain multi-polar spindles, indicating aberrant spindle formation, resulting in mitotic arrest and rapid cell death

endocrine/exocrine glands
increased T cell derived lymphoma incidence ( J:179414 )
• in the absence of 4OHT, mutants develop thymic lymphoma tumors

immune system
increased T cell derived lymphoma incidence ( J:179414 )
• in the absence of 4OHT, mutants develop thymic lymphoma tumors

hematopoietic system
increased T cell derived lymphoma incidence ( J:179414 )
• in the absence of 4OHT, mutants develop thymic lymphoma tumors




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
12/10/2024
MGI 6.24 		The Jackson Laboratory